Ratios Reveal: Breaking Down Oncology Institute Inc (TOI)’s Financial Health

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

Oncology Institute Inc (NASDAQ: TOI) closed the day trading at $0.68 down -24.00% from the previous closing price of $0.90. In other words, the price has decreased by -$24.00 from its previous closing price. On the day, 0.82 million shares were traded. TOI stock price reached its highest trading level at $0.8858 during the session, while it also had its lowest trading level at $0.6449.


For a better understanding of TOI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.83 and its Current Ratio is at 3.08. In the meantime, Its Debt-to-Equity ratio is 2.90 whereas as Long-Term Debt/Eq ratio is at 2.75.

On September 14, 2022, Guggenheim started tracking the stock assigning a Buy rating and target price of $7.

On August 15, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $10.Jefferies initiated its Buy rating on August 15, 2022, with a $10 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 29 ’24 when Havencrest Healthcare Partners sold 8,637 shares for $2.12 per share. The transaction valued at 18,310 led to the insider holds 0 shares of the business.

Havencrest Healthcare Partners sold 6,979 shares of TOI for $14,935 on Jan 26 ’24. The 10% Owner now owns 8,637 shares after completing the transaction at $2.14 per share. On Jan 25 ’24, another insider, Havencrest Healthcare Partners, who serves as the 10% Owner of the company, sold 11,882 shares for $2.07 each. As a result, the insider received 24,596 and left with 15,616 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOI now has a Market Capitalization of 50830368 and an Enterprise Value of 103701632. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.15 while its Price-to-Book (P/B) ratio in mrq is 1.23. Its current Enterprise Value per Revenue stands at 0.32 whereas that against EBITDA is -1.911.

Stock Price History:

The Beta on a monthly basis for TOI is 0.79, which has changed by 0.59069765 over the last 52 weeks, in comparison to a change of 0.2644323 over the same period for the S&P500. Over the past 52 weeks, TOI has reached a high of $2.65, while it has fallen to a 52-week low of $0.33. The 50-Day Moving Average of the stock is -49.56%, while the 200-Day Moving Average is calculated to be -56.50%.

Shares Statistics:

Over the past 3-months, TOI traded about 126.09K shares per day on average, while over the past 10 days, TOI traded about 259560 shares per day. A total of 74.15M shares are outstanding, with a floating share count of 31.09M. Insiders hold about 58.17% of the company’s shares, while institutions hold 20.78% stake in the company. Shares short for TOI as of 1714435200 were 268416 with a Short Ratio of 2.13, compared to 1711584000 on 262704. Therefore, it implies a Short% of Shares Outstanding of 268416 and a Short% of Float of 0.5499999999999999.

Earnings Estimates

The dynamic stock of Oncology Institute Inc (TOI) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.On average, analysts expect EPS of -$0.12 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.12, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.

Analysts are recommending an EPS of between -$0.36 and -$0.36 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.17, with 1.0 analysts recommending between -$0.17 and -$0.17.

Revenue Estimates

1 analysts predict $94.67M in revenue for the current quarter. It ranges from a high estimate of $95.16M to a low estimate of $95.16M. As of the current estimate, Oncology Institute Inc’s year-ago sales were $76.19MFor the next quarter, 1 analysts are estimating revenue of $102.46M. There is a high estimate of $102.46M for the next quarter, whereas the lowest estimate is $102.46M.

A total of 1 analysts have provided revenue estimates for TOI’s current fiscal year. The highest revenue estimate was $412.5M, while the lowest revenue estimate was $412.5M, resulting in an average revenue estimate of $412.5M. In the same quarter a year ago, actual revenue was $324.24MBased on 1 analysts’ estimates, the company’s revenue will be $482.8M in the next fiscal year. The high estimate is $482.8M and the low estimate is $482.8M.

Most Popular

[the_ad id="945"]